Last 27 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.29 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 22.48 | 31.80 | 5.69 | 41.97 | 14.98 | 39.19 | 42.73 | 29.45 | 29.73 | 33.30 | 45.25 | 50.45 | 46.40 |
| — | -18.8% | -86.7% | +42.5% | -49.6% | +17.7% | -5.6% | -41.6% | -35.9% | -25.1% | +27.8% | +555.0% | +181.1% | |
| P/B Ratio | 1.45 | 1.13 | 0.90 | 1.56 | 1.02 | 0.65 | 0.82 | 0.71 | 0.78 | 1.17 | 1.44 | 1.13 | 1.56 |
| — | +73.8% | +9.5% | +119.3% | +29.7% | -44.7% | -43.3% | -36.8% | -49.8% | -34.6% | -41.7% | -54.9% | -37.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
AbCellera Biologics Inc.'s operating margin was -691.7% in Q1 2026, down 628.0 pp QoQ and up 787.8 pp YoY. The trailing four-quarter average of -474.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 104.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.6% | -4.1% | 82.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -104.1% | -17.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +7.8% | +17.4% | +12.8% | |
| Operating Margin | -289.0% | -691.7% | -63.7% | -851.8% | -290.2% | -1479.6% | -1440.7% | -1439.4% | -1276.2% | -551.5% | -719.6% | -831.8% | -511.0% |
| — | +53.2% | +95.6% | +40.8% | +77.3% | -168.3% | -100.2% | -73.1% | -149.7% | -3.6% | -310.4% | -2334.8% | -2694.8% | |
| Net Margin | -194.9% | -519.1% | -19.9% | -637.8% | -203.3% | -1077.2% | -677.4% | -785.4% | -504.3% | -408.0% | -513.7% | -433.6% | -303.6% |
| — | +51.8% | +97.1% | +18.8% | +59.7% | -164.0% | -31.9% | -81.2% | -66.1% | -24.0% | -270.2% | -1750.9% | -1954.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -13.3% | -4.2% | -0.8% | -5.8% | -3.4% | -4.4% | -3.2% | -4.7% | -3.3% | -3.6% | -4.0% | -2.4% | -2.5% |
| — | +5.4% | +73.5% | -24.1% | -3.8% | -23.3% | +20.6% | -94.0% | -29.7% | -8.3% | -67.7% | -211.3% | -353.1% | |
| ROA | -10.8% | -3.2% | -0.7% | -4.1% | -2.5% | -3.4% | -2.5% | -3.6% | -2.6% | -2.8% | -3.1% | -1.9% | -2.0% |
| — | +3.9% | +73.5% | -13.7% | +1.5% | -22.6% | +20.9% | -94.2% | -27.7% | -4.3% | -62.6% | -210.9% | -372.3% | |
| ROIC | -15.5% | -4.0% | -2.0% | -5.5% | -3.7% | -5.0% | -5.5% | -6.8% | -6.6% | -3.8% | -4.5% | -3.8% | -3.5% |
| — | +18.3% | +63.7% | +19.4% | +43.6% | -31.0% | -21.2% | -81.6% | -89.0% | +21.2% | -50.5% | -193.9% | -223.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 38.5% YoY to 14.05x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.15 | 0.13 | 0.15 | 0.14 | 0.07 | 0.06 | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 |
| — | +125.3% | +102.7% | +122.8% | +117.5% | +1.8% | -7.8% | -3.0% | -7.8% | -5.3% | +0.7% | +12.2% | +131.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.32 | 14.05 | 11.32 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.76 | 7.33 | 8.34 | 7.83 |
| — | +38.5% | +15.5% | +8.2% | +1.0% | +30.7% | +33.9% | +11.9% | +40.1% | -26.1% | -15.5% | -15.4% | +51.3% | |
| Quick Ratio | 11.23 | 14.05 | 11.23 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.75 | 7.32 | 8.33 | 7.82 |
| — | +38.5% | +14.5% | +8.2% | +1.0% | +30.9% | +34.0% | +12.1% | +40.3% | -26.0% | -15.4% | -13.4% | +54.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABCL stock.
AbCellera Biologics Inc.'s current P/E is -11.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AbCellera Biologics Inc.'s current operating margin is -289.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AbCellera Biologics Inc.'s business trajectory between earnings reports.